Neuberger Berman Group LLC Buys 9,791 Shares of QIAGEN N.V. $QGEN

Key Points

• Neuberger Berman Group LLC increased its holdings in Qiagen N.V. by 102.4% in Q1, acquiring an additional 9,791 shares and bringing its total to 19,352 shares valued at approximately $767,000.
• Qiagen reported Q2 earnings of $0.60 EPS, meeting analyst expectations, with a revenue of $533.54 million, up 7.7% year-over-year.
• The company announced a $0.25 per share dividend with a yield of 52.0%, reflecting a dividend payout ratio of 14.79%.

Neuberger Berman Group LLC raised its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 102.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,352 shares of the company's stock after acquiring an additional 9,791 shares during the period. Neuberger Berman Group LLC's holdings in QIAGEN were worth $767,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in QGEN. Exchange Traded Concepts LLC lifted its stake in QIAGEN by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after acquiring an additional 395 shares during the period. LPL Financial LLC lifted its stake in QIAGEN by 2.6% in the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after acquiring an additional 432 shares during the period. Commerce Bank lifted its stake in QIAGEN by 20.4% in the fourth quarter. Commerce Bank now owns 5,931 shares of the company's stock worth $264,000 after acquiring an additional 1,004 shares during the period. Cetera Investment Advisers lifted its stake in QIAGEN by 14.4% in the fourth quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after acquiring an additional 1,418 shares during the period. Finally, GAMMA Investing LLC lifted its stake in QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after acquiring an additional 1,425 shares during the period. Institutional investors own 70.00% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on QGEN. Cowen reaffirmed a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Barclays initiated coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Bank of America lifted their price target on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Finally, UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $49.69.

QIAGEN Stock Performance

NYSE QGEN traded up $0.1950 during trading hours on Thursday, hitting $49.3950. The company's stock had a trading volume of 224,452 shares, compared to its average volume of 1,370,260. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The company's 50 day simple moving average is $48.53 and its two-hundred day simple moving average is $43.81. The company has a market cap of $10.98 billion, a P/E ratio of 29.19, a price-to-earnings-growth ratio of 2.58 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same period last year, the company earned $0.55 EPS. QIAGEN's revenue for the quarter was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, sell-side analysts expect that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

QIAGEN Dividend Announcement

The company also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. This represents a dividend yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. QIAGEN's payout ratio is currently 14.79%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.